[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-pain":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,331,0,25,[9,45,71,91,114,143,167,188,211,241,267,292,313,337,364,386,409,440,469,489,514,533,564,591,610],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053346","examining-racial-and-socioeconomic-differences-in-chronic-low-back-pain-100053346",false,"NCT05991440","Examining Racial and Socioeconomic Differences in Chronic Low Back Pain","Racial and Socioeconomic Differences in Chronic Low Back Pain","ERASED","Inclusion:\n\n* Non-specific cLBP that has persisted for at least 3 months and has resulted in pain on at least half the days in the past 6 months.\n* Age 18 - 85; the lower end of this age range was chosen to capture the growing prevalence of young adults with cLBP, and participants over 85 years are increasingly likely to meet one or more exclusion criteria.\n* Participants report ethnic group as non-Hispanic and racial group as either Black\u002FAfrican American or White\u002FCaucasian.\n\nExclusion:\n\n* Low back pain that is attributable to other factors such as ankylosing spondylitis, infection, malignancy, compression fracture of other trauma.\n* Systemic rheumatic disease\u002Fcondition (e.g. rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia).\n* Any other chronic pain condition that the participant believes to be more prominent or severe than the low back pain.\n* A history of clinically significant surgery to the low back within the past year.\n* Uncontrolled hypertension (i.e. SBP\u002FDBP of \\> 150\u002F95), cardiovascular or peripheral arterial disease.\n* Poorly controlled diabetes (HbA1c \\> 8%).\n* Neurological disease (e.g. Parkinson's, multiple sclerosis, epilepsy).\n* Serious psychiatric disorder requiring hospitalization within the past 12 months or characterized by active suicidal ideation.\n* Diminished cognitive function that would interfere with understanding of study procedures.","ALL","18 Years","85 Years",{"count":22,"type":23},240,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to gain a better understanding of how people's racial background and socioeconomic status (e.g., income, education, and employment) impact their experiences of chronic low back pain (cLBP).",[27],"Chronic Pain",[29,30,31],"lower back pain","Race","Socioeconomic","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2024-04-22",{"date":40,"type":23},"2028-12-31",{"name":42,"class":43},"Washington University School of Medicine","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100054326","dose-response-effects-of-a-brief-audio-guided-mindfulness-intervention-for-acute-pain-100054326","NCT07562412","Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain","Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain While Awaiting Orthopedic Care","Inclusion Criteria:\n\n* Receiving treatment at Tallahassee Orthopedic Center\n* Understanding English instructions fluently\n* Being 18 years of age or older\n\nExclusion Criteria:\n\n* Unable to consent because of physical or mental incapacity.",{"count":53,"type":23},300,"INTERVENTIONAL",[56],"NA","This project is a single-site, three-arm, randomized controlled trial investigating whether different length audio-recorded mindfulness practices differentially decrease pain among patients in a waiting room awaiting orthopedic care.",[59,60,61,62,63,27],"Pain","Pain Management","Mindfulness","Orthopedic","Acute Pain",{"date":35,"type":36},{"date":66,"type":36},"2026-04-29",{"date":68,"type":23},"2027-04-30",{"name":70,"class":43},"Florida State University",{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100054181","patient-retrospective-outcomes-pro-100054181","NCT01550575","Patient Retrospective Outcomes (PRO)","PRO","Key Inclusion Criteria:\n\n* Previously treated with or eligible for use with Boston Scientific Systems\n* 18 years of age or older at the start of Baseline",{"count":79,"type":23},15000,"This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.",[27],{"date":35,"type":36},{"date":84,"type":36},"2012-04-03",{"date":86,"type":23},"2030-12",{"name":88,"class":89},"Boston Scientific Corporation","INDUSTRY",144,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":54,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":110,"leadSponsor":112,"locationsCount":44},"100053616","virtual-intelligence-for-transformative-lifestyle-solutions-in-pain-100053616","NCT07124598","Virtual Intelligence for Transformative Lifestyle Solutions in Pain","VITALS-Pain","Inclusion Criteria:\n\n* Patients with opioid misuse or International Classification of Diseases 10th revision (ICD-10) diagnosis of opioid use disorder\n* Patients with Chronic pain of at least moderate intensity (\\>4 Pain Intensity Score) with no pain medication changes in 14 days\n* Ability to understand written\u002Fspoken instruction and provide informed consent in English\n* Ability and willingness to participate in all components of the study\n\nExclusion Criteria:\n\n* History of severe motion sickness, cybersickness, or conditions that could make participation in VR hazardous or cause adverse effects\n* Conditions that could prevent proper use of VR headset (such as vision problems that cannot be corrected by contact lenses or glasses that fit in VR, Significant hearing impairments that cannot be corrected by a hearing device)\n* History of seizures or seizure disorder\n* Acute exacerbation of psychiatric conditions such as self-injurious behaviors or suicidal risk that preclude the ability to participate in the study",{"count":99,"type":23},15,[56],"This pilot study aims to evaluate the feasibility and acceptability of a VR-based chronic pain management intervention with a virtual AI coach for patients with Opioid misuse and opioid use disorder (OM\u002FOUD). The intervention is a single-day 45-minute VR intervention which is subdivided into three smaller sessions:\n\nSession 1: A 15-minute AI check-in to ask questions about biopsychosocial health, Session 2: A 20-minute Pain Coping Skills Training (PCST) session offering psychoeducation on managing chronic pain Session 3: A 10-minute stress reduction exercise.\n\nThe VR sessions will be conducted using hardware (VR Headset Device - Meta Quest 3) and software developed by AugMend Health Company.\n\nThe study will be conducted in a clinical setting at the Montefiore Multidisciplinary Pain Medicine Program (MMPP), a Pain Medicine outpatient specialty practice within a major urban medical center. MMPP providers see thousands of patients every month, some of which have concurrent opioid misuse or OM\u002FOUD.",[27],[104,105,106,107],"Virtual Reality (VR)-based Chronic Pain Management","Opioid Management","Opioid Use Disorder","Artificial Intelligence (AI)",{"date":35,"type":36},{"date":33,"type":36},{"date":111,"type":23},"2026-12",{"name":113,"class":43},"Montefiore Medical Center",{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":54,"phases":123,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":142},"100520596","assessing-the-efficacy-of-an-acceptance-based-digital-intervention-for-veterans-with-chronic-pain-100520596","NCT06058624","Assessing the Efficacy of an Acceptance-Based Digital Intervention for Veterans With Chronic Pain","Assessing the Efficacy of an Acceptance-Based Digital Intervention to Improve Functioning for Veterans With Chronic Pain","VACT-CP","Inclusion Criteria:\n\n* Current diagnosis of non-cancer chronic pain, defined by:\n\n  * 1a at least one pain-related diagnosis indicated by an ICD-9 or -10 code related to either Musculoskeletal pain or Joint Problems\u002FOsteoarthritis\n  * 1b. minimum Grade 1 or 2 on the Graded Chronic Pain Scale\n* Has a computer and working, high-speed wireless internet connection at home\n* Competent to provide written informed consent\n\nExclusion Criteria:\n\n* Any current or lifetime DSM-5 psychotic disorder\n* Current or recent (within 1 month of study entry) DSM-5 substance use disorder\n* Current use of any other chronic pain-related psychological treatment\n* Clinically significant suicidality within the past year\n* Any cognitive or physical impairment that would interfere with study participation of using a computer and providing feedback",{"count":22,"type":23},[56],"Pain has been identified as among the most frequent presenting medical complaints, in particular within primary care for Veterans. There are few areas of daily living and functioning that pain intensity does not impact, with reported pain intensity related to difficulties in social situations and changes in activities of daily life, sleep, and appetite. Therapeutic interventions such as Acceptance and Commitment Therapy for Chronic Pain (ACT-CP) that target issues related to the cognitions and emotional concerns related to chronic pain have been well-documented for reduction of associated psychiatric symptoms and modest pain relief. At the same time, online programming can improve the ability of pain psychoeducation programs and ACT-CP to reach patients. The proposed project will compare online Veteran ACT for Chronic Pain (VACT-CP) compared to another pain program, Online Pain School, to evaluate how they assist Veterans with chronic pain to improve their functioning, pain management, and quality of life.",[27],[27,127,128,129,130,131],"Internet-Based Intervention","Psychosocial Intervention","Acceptance and Commitment Therapy","Quality of Life","Veterans","2026-06-30",{"date":134,"type":36},"2026-07-02",{"date":136,"type":36},"2024-07-31",{"date":138,"type":23},"2027-10-31",{"name":140,"class":141},"VA Office of Research and Development","FED",3,{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":54,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":44},"100645356","performance-and-safety-of-the-antalgeek-thess-monitoring-medical-device-in-the-outpatient-management-of-acute-pain-and-postoperative-recovery-100645356","NCT07680998","Performance and Safety of the ANTALGEEK® Thess Monitoring Medical Device in the Outpatient Management of Acute Pain and Postoperative Recovery","Evaluation of the Performance and Safety of the ANTALGEEK® Thess Monitoring Medical Device in the Outpatient Management of Acute Pain and Postoperative Recovery - A Single-Center, Randomized, Controlled Proof-of-Concept Study.","TRACE","Inclusion Criteria:\n\n* Patients eligible for outpatient surgery.\n* Patients undergoing surgery likely to result in moderate to severe pain.\n* Patients available for a 3-month follow-up.\n* Patients who have provided their free and informed consent.\n* Patients who have signed the consent form.\n* Patients enrolled in or covered by a health insurance plan.\n\nExclusion Criteria:\n\n* Patients participating in an interventional RIPH study involving a drug or classified as Category 1.\n* Patients in an exclusion period determined by another study.\n* Patients under judicial protection, guardianship, or conservatorship.\n* Patients unable to express consent.\n* Patient for whom it is impossible to provide informed information.\n* Pregnant, laboring, or breastfeeding patients.",{"count":152,"type":23},150,[56],"Acute postoperative pain (APOP) is a major public health problem, affecting nearly 10 million patients in France each year. Effective analgesic therapy in the first postoperative week is a key factor in reducing early postoperative morbidity and mortality. Poorly controlled APOP is a major risk factor for chronic postoperative pain. In France today, more and more patients undergo surgical procedures as outpatients. The challenge is to manage postoperative pain in the homes of patients who have undergone increasingly complex surgical procedures, either after outpatient surgery or after a prompt return home as part of an Enhanced Recovery After Surgery (ERAS) protocol. In outpatient surgery, postoperative pain management requires new strategies and\u002For organizational approaches to ensure high-quality pain management from the very start. The principle of analgesia for acute postoperative pain recommends: i) routine, fixed-schedule maintenance therapy; and ii) rescue therapy if maintenance therapy is insufficient, based on pain titration, using mild or strong oral opioids. Postoperative pain is the primary focus of postoperative care but the goal is also to improve postoperative recovery and enhance the patient's overall care. To date, there are no medical telemonitoring devices to support the patient in properly taking their analgesics based on multiple-daily assessments of the efficacy and tolerability of the analgesic treatment, enabling systematic postoperative screening for early and late warning signs of the risk of chronic pain. The Thess Monitoring device, which implements the ANTALGEEK® protocol, (TMA) was developed to optimize the efficiency of outpatient management of acute postoperative pain. It improves patients' adherence to maintenance treatment with adaptive, personalized control of analgesia through better use of opioid rescue therapy, and the reduction of adverse effects associated with improper opioid use (under- or over-dosing). The aim is to ensure optimal pain resolution and improve early and late postoperative recovery during the first postoperative week. The TMA system enables remote monitoring of the efficacy and tolerability of analgesic treatment, as well as early and late warning signs of the risk of chronic pain. By measuring pain scores daily during the first postoperative week, it identifies patients with a suboptimal pain trajectory who are at high risk of developing persistent pain beyond the third month. It also assesses warning signs of the risk of chronic pain (neuropathic pain, persistent opioid use) at intervals following the procedure (Day 8, Month 1, Month 2, Month 3). Improving the patient care pathway via the TMA system should make it possible to better coordinate postoperative follow-up between hospital-based and community-based care.",[156,27],"Post Operative Pain",[156,60,158],"Monitoring","2026-06-26",{"date":134,"type":36},{"date":162,"type":36},"2025-12-01",{"date":164,"type":23},"2026-12-31",{"name":166,"class":43},"Centre Hospitalier Universitaire de Nīmes",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":173,"sex":18,"minAge":174,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100454469","anatomical-and-functional-imaging-correlates-of-chronic-pain-in-cerebral-palsy-100454469","NCT05197946","Anatomical and Functional Imaging Correlates of Chronic Pain in Cerebral Palsy","Participants with CP (Survey-only):\n\nInclusion Criteria:\n\n* Individual 8+ years of age\n* Diagnosis of cerebral palsy\n\nExclusion Criteria:\n\n-None\n\nNeurotypical participants: (Survey-only):\n\nInclusion Criteria:\n\n* Individual 8+ years of age\n* Adult subject able to indicate understanding and affirmative consent OR Adult\u002Fchild subject unable to indicate understanding and affirmative consent AND subject assents AND LAR consents\n\nExclusion Criteria:\n\n-Clinically-significant neurologic or developmental diagnosis\n\nParticipants with CP (Survey and MRI):\n\nInclusion Criteria:\n\n* Individual 8+ years of age\n* Adult subject able to indicate understanding and affirmative consent OR Adult subject unable to indicate understanding and affirmative consent AND subject assents AND LAR consents\n* Diagnosis of cerebral palsy\n* Clinical imaging demonstrating isolated periventricular white matter injury\n* Clinical judgment that all neurologic symptoms are attributable to non-progressive periventricular white matter injury\n* Able to lie still in scanner for 1.5 hours in at most 2 sessions and be able to have MRI\n\nExclusion Criteria:\n\n-None\n\nNeurotypical participants (Survey and MRI):\n\nInclusion Criteria:\n\n* Individual 8+ years of age\n* Adult subject able to indicate understanding and affirmative consent\n* Able to lie still in scanner for 1.5 hours and be able to have MRI\n\nExclusion Criteria:\n\n-Clinically-significant neurologic or developmental diagnosis",true,"8 Years",{"count":53,"type":23},"The investigators hope to use MRI biomarkers to identify and characterize sensorimotor network disruption patterns associated with chronic pain and sensory deficits in CP. Investigators will use existing information in the medical record as well as subjective reports from interview, physical exam data, and anatomical and functional MRI data to non-invasively identify brain injury correlates of pain and sensory deficits.",[178,27],"Cerebral Palsy",{"date":180,"type":36},"2026-06-29",{"date":182,"type":36},"2018-12-04",{"date":184,"type":23},"2028-12",{"name":186,"class":43},"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",4,{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":54,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":44},"100645403","docktales-for-chronic-pain-100645403","NCT07680894","DockTales for Chronic Pain","Evaluating Feasibility and Acceptability of DockTales for Chronic Pain","Inclusion Criteria:\n\n* Age ( 18-88 years old)\n* English speaker (written and spoken)\n* Chronic pain for at least 3 months\n* Smartphone\u002Ftext messaging capability\n\nExclusion Criteria:\n\n* Any personal history of mania, schizophrenia, or other psychoses\n* Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.\n* Pregnancy or breast feeding\n* Impaired or uncorrected hearing","88 Years",{"count":197,"type":23},60,[56],"This study will evaluate the feasibility and acceptability of DockTales, a mobile health tool designed for adults with chronic pain. DockTales supports pain and sleep tracking through brief diaries, body-map pain reporting, reflective journaling, visual summaries, and optional AI-supported interaction. The study will be conducted completely remotely. Participants will complete 2 weeks of DockTales use and 2 weeks of REDCap-based daily monitoring, with the order randomized. The main goal is to determine whether DockTales is usable, acceptable, engaging, and practical for adults with chronic pain compared with standard REDCap monitoring.",[27,201],"Chronic Pain Syndrome","NOT_YET_RECRUITING","2026-06-25",{"date":134,"type":36},{"date":206,"type":23},"2026-07-17",{"date":208,"type":23},"2027-10-24",{"name":210,"class":43},"University of Maryland, Baltimore",{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100645231","emotional-allodynia-questionnaire-aeq-in-fibromyalgia-pearl-100645231","NCT07677631","Emotional Allodynia Questionnaire (AEQ) in Fibromyalgia (PEARL)","Pain, Emotional Allodynia, and Relational Load (PEARL): A Multicenter Validation Study of the Emotional Allodynia Questionnaire in Fibromyalgia","PEARL","CASES (fibromyalgia)\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Clinical diagnosis of fibromyalgia confirmed according to the 2016 revision of the ACR criteria\n* Chronic non-cancer pain for at least 3 months\n* Ability to understand and independently complete self-report questionnaires in Italian\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Active oncological disease or cancer-related pain\n* Any current or past psychiatric diagnosis except Major Depressive Disorder and Panic Disorder (assessed by clinical history)\n* Severe cognitive impairment precluding questionnaire completion\n* Inability to understand or complete questionnaires in Italian\n\nCONTROLS (non-fibromyalgia chronic pain)\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Chronic non-cancer pain for at least 3 months with a defined nociceptive or neuropathic generator (e.g., radiologically or surgically documented degenerative, structural, or post-surgical musculoskeletal pain, or neuropathic pain with an identifiable neurological lesion or disease)\n* Not meeting the 2016 ACR criteria for fibromyalgia\n* Ability to understand and independently complete self-report questionnaires in Italian\n* Willingness to provide written informed consent\n\nExclusion Criteria (parallel to cases):\n\n* Diagnosis of fibromyalgia or another recognized nociplastic primary pain condition (e.g., primary chronic widespread pain)\n* Active oncological disease or cancer-related pain\n* Any current or past psychiatric diagnosis except Major Depressive Disorder and Panic Disorder\n* Severe cognitive impairment precluding questionnaire completion\n* Inability to understand or complete questionnaires in Italian\n\nNote: ongoing pharmacological treatment for pain or mental health is not an exclusion criterion in either group; Major Depressive Disorder and Panic Disorder are recorded at baseline and used in covariate-adjusted and stratified analyses.",{"count":220,"type":23},423,"The Emotional Allodynia Questionnaire (AEQ) is an 11-item self-report instrument that measures disproportionate emotional reactivity to low-intensity interpersonal cues(perceived unresponsiveness, exclusion, loss of reciprocity), a pattern termed emotional allodynia. It was preliminarily validated in a single-center fibromyalgia sample. PEARL (validation phase) is a multicenter, prospective, observational psychometric validation study that (1) replicates the internal structure and convergent validity of the AEQ in an independent fibromyalgia sample, (2) tests its known-groups (discriminative) accuracy in separating fibromyalgia from non-fibromyalgia chronic pain of defined nociceptive or neuropathic origin, expressed as the area under the ROC curve (AUC), and (3) assesses test-retest reliability. There is no intervention.",[223,27,224],"Fibromyalgia","Nociplastic Pain",[226,223,227,228,229,230],"Emotional Allodynia Questionnaire","Nociplastic pain","Psychometric validation","Central sensitization","Emotion regulation","2026-06-24",{"date":233,"type":36},"2026-07-01",{"date":235,"type":36},"2025-09-10",{"date":237,"type":23},"2027-08",{"name":239,"class":43},"University of Bari",5,{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":54,"phases":252,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":44},"100552800","improving-sleep-in-veterans-with-the-polytrauma-clinical-triad-100552800","NCT06477796","Improving Sleep in Veterans With the Polytrauma Clinical Triad","A Sleep Intervention to Improve Quality of Life and Symptom Management in Veterans With the Polytrauma Clinical Triad","LIONv2","Inclusion Criteria:\n\n* Veteran\n* English speaking with phone and internet access\n* Current self-reported sleep disturbances\n* Clinical stable for current pharmacologic or behavioral health treatments for depression, anxiety, sleep and pain\n* Documented history of TBI\n\nExclusion Criteria:\n\n* Decisional impairment and\u002For dementia\n* Current usage of a lightbox or negative ion generator\n* Shift work\n* History of macular degeneration and\u002For bipolar disorder\n* Evidence for suicidal ideation\n* Cancer diagnosis within the past 6 months\n* Surgery within the past 6 months\n* Substance abuse within the past 6-12 months\n* Significant impairing post-stroke residual hemiparesis","89 Years",{"count":251,"type":23},96,[56],"The \"polytrauma clinical triad\" (PCT), a highly disabling constellation of factors, is defined by the coexistence of traumatic brain injury, post-traumatic stress disorder, and chronic pain. Veterans with the PCT are medically complex, often refractory to conventional therapies, and suffer from additional related chronic sequela. Notably, sleep disturbances and cognitive impairment, which the investigators hypothesize are significant contributing factors to these functional impairments and an impediment toward rehabilitation. Thus, the investigators' research aims to intervene \"at the level of sleep\", and by improving sleep, improve these interconnected, disabling, and difficult to treat enduring complexities associated with the PCT - ultimately to improve Veteran quality of life, functional independence, and restorative function. The investigators predict that the proposed intervention, morning bright light therapy, which is cost-effective, rapidly deployable and home-based, will be effective in improving sleep and overall PCT symptom management, thereby, resulting in a measurable and impactful improvement in quality of life.",[255,256,27],"Traumatic Brain Injury","Post-traumatic Stress Disorder",[258,259,260],"polytrauma clinical triad","TBI","PTSD",{"date":180,"type":36},{"date":263,"type":36},"2025-05-01",{"date":265,"type":23},"2028-09-29",{"name":140,"class":141},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":277,"conditions":278,"keywords":279,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":291},"100644649","turkish-adaptation-of-the-pain-and-smoking-inventory-100644649","NCT07673926","Turkish Adaptation of the Pain and Smoking Inventory","Turkish Cultural Adaptation and Psychometric Properties of the Pain and Smoking Inventory in Individuals With Chronic Pain","Inclusion Criteria:\n\n* Aged 18 years and older.\n* Having a diagnosis of chronic pain that has persisted for at least 3 months.\n* Smoking at least 5 cigarettes per day (within the last 30 days).\n* Being able to read and write in Turkish.\n* Volunteering to participate in the study and signing the written informed consent form.\n\nExclusion Criteria:\n\n* Having a diagnosis of active psychosis or severe depression.\n* Having a diagnosis of cognitive impairment or intellectual disability.\n* Having severe alcohol dependence or substance use disorder.\n* Having reading and writing difficulties to a degree that prevents completing the questionnaire independently.\n* Being in the pregnancy or breastfeeding period.\n* Using nicotine replacement therapy or smoking cessation medication within the last 1 month.","65 Years",{"count":276,"type":23},200,"The purpose of this study is to perform the Turkish cross-cultural adaptation of the Pain and Smoking Inventory (PSI) and to comprehensively evaluate its reliability, validity, and psychometric properties among daily cigarette smokers with chronic pain.",[27],[280,281,282],"chronic pain","smoking","Cross-Cultural Adaptation","2026-06-23",{"date":180,"type":36},{"date":286,"type":23},"2026-09-01",{"date":288,"type":23},"2027-06-30",{"name":290,"class":43},"Hacettepe University",2,{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":310,"leadSponsor":312,"locationsCount":291},"100644710","validation-of-the-turkish-brief-inventory-of-treatment-expectations-in-chronic-pain-100644710","NCT07673874","Validation of the Turkish Brief Inventory of Treatment Expectations in Chronic Pain","Turkish Cross-Cultural Adaptation, Validity, and Reliability of the \"Brief Inventory of Treatment Expectations in Chronic Pain\" (BITEC) Scale","BITEC-TR","Inclusion Criteria:\n\n* Aged 18-70 years\n* Having chronic pain for at least 3 months according to the International Association for the Study of Pain (IASP) criteria\n* Diagnosed with any chronic pain condition (e.g., fibromyalgia, nociceptive pain, neuropathic pain, etc.)\n* Being literate\n* Currently receiving any medical treatment\n\nExclusion Criteria:\n\n* Presence of cancer-related pain\n* Diagnosis of acute pain\n* Being unable to fill out the questionnaire due to a diagnosed cognitive impairment or psychiatric illness\n* Presence of visual or motor disabilities that prevent completing the questionnaire","70 Years",{"count":302,"type":23},250,"The purpose of this study is to conduct the Turkish cross-cultural adaptation, validity, and reliability study of the \"Brief Inventory of Treatment Expectations in Chronic Pain\" (BITEC) scale. Chronic pain is a complex, multidimensional experience that affects a significant portion of the adult population. Treatment expectations play a critical role in predicting clinical outcomes and directly influencing placebo\u002Fnocebo responses. While several tools exist to evaluate expectations, there is a lack of a concise, clinician-friendly, and Item Response Theory (IRT)-based instrument adapted for Turkish chronic pain populations. The BITEC is a 9-item scale that evaluates biological, psychological, and social\u002Finteractional expectation domains.\n\nThis methodological and cross-sectional study will be conducted with adult patients diagnosed with chronic pain for at least three months at Bingöl State Hospital. The study will be carried out in four consecutive stages: cross-cultural adaptation (forward and backward translation), comprehensibility pre-testing (with 30-40 volunteers), main data collection (with at least 200 participants), and statistical analyses. Data will be collected through printed forms and an online survey platform (Kobotoolbox), involving no clinical interventions. Participants will complete a sociodemographic information form, the Turkish version of the BITEC (BITEC-TR), the Treatment Expectations in Chronic Pain Scale (TEC-TR), the Pain Catastrophizing Scale (PCS), the Numerical Pain Rating Scale (NPRS), and the Hospital Anxiety and Depression Scale (HADS). Additionally, a subgroup of approximately 60 participants will recomplete the BITEC-TR 7-10 days after the initial session to evaluate test-retest reliability. Psychometric evaluation will include construct validity through exploratory and confirmatory factor analyses, and internal consistency and stability measurements.",[27],[306,307,280,282],"treatment expectation","validation study",{"date":180,"type":36},{"date":286,"type":23},{"date":311,"type":23},"2027-08-31",{"name":290,"class":43},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":54,"phases":322,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":44},"100535030","real-world-efficacy-of-evoke-closed-loop-spinal-cord-stimulation-cl-scs-therapy-in-chronic-pain-patients-ultra-100535030","NCT06246526","Real-World Efficacy of Evoke® Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy in Chronic Pain Patients (ULTRA).","ULTRA","Inclusion Criteria:\n\nBe 18 years of age or older at the time of enrollment.\n\nDiagnosed with chronic, intractable pain of the trunk and\u002For limbs, which has been refractory to conservative therapy for a minimum of 6 months.\n\nSubject has a minimum Visual Analog Scale (VAS) score of 60 mm or higher (where 100 mm indicates the worst imaginable pain) at baseline.\n\nBe an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician.\n\nBe willing and capable of giving informed consent.\n\nBe willing and able to comply with study-related requirements, procedures, and visits.\n\nExclusion Criteria:\n\nSubject is pregnant or nursing.\n\nHave a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, as determined by the Investigator.\n\nHave evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention, and\u002For ability to evaluate treatment outcomes.\n\nHave an existing drug pump and\u002For SCS system or another active implantable device such as a pacemaker, deep brain stimulator (DBS), or sacral nerve stimulator (SNS).\n\nHave prior experience with SCS.\n\nBe concomitantly participating in another clinical study.",{"count":321,"type":23},50,[56],"This observational, prospective data collection is designed to evaluate the efficacy of CL-SCS therapy in real-world patients suffering from chronic pain.",[59,27,325],"Neuropathic Pain",[327,328],"Saluda","Spinal Cord Stimulation","2026-06-22",{"date":283,"type":36},{"date":332,"type":36},"2024-01-30",{"date":334,"type":23},"2027-12-31",{"name":336,"class":43},"Saint Francis Hospital",{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":54,"phases":346,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":4},"100641455","phase-1-safety-and-preliminary-efficacy-of-endoscopic-submucosal-injection-of-hyaluronic-acid-into-the-bladder-wall-in-patients-with-interstitial-cystitisbladder-pain-syndrome-icbps-100641455","NCT07658118","Safety and Preliminary Efficacy of Endoscopic Submucosal Injection of Hyaluronic Acid Into the Bladder Wall in Patients With Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS)","A Pilot Open-Label Prospective Study of Safety and Preliminary Efficacy of Endoscopic Submucosal Injection of Hyaluronic Acid Into the Bladder Wall in Patients With Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS)","HA-IC\u002FBPSPilot","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years.\n* Confirmed diagnosis of Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS) based on cystoscopic findings (glomerulations after hydrodistension or Hunner's lesions).\n* Refractory to at least 2 lines of standard therapy (e.g., dietary modifications, oral medications, intravesical hyaluronic acid instillations, hydrodistension) for ≥ 6 months.\n* Pain score ≥ 4 on a 0-10 Visual Analog Scale (VAS) at screening.\n* Ability and willingness to provide written informed consent and to complete a 3-day voiding diary.\n\nExclusion Criteria:\n\n* Active urinary tract infection (bacteriuria \\> 10⁴ CFU\u002FmL).\n* History of genital herpes.\n* Severe renal failure (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n* Known allergy to hyaluronic acid or any component of the study product.\n* Pregnancy or breastfeeding.\n* Psychiatric disorders or substance abuse that would interfere with study participation.\n* Participation in another clinical study within 30 days prior to enrollment.",{"count":99,"type":23},[347],"PHASE1","The goal of this pilot clinical trial is to learn if injecting hyaluronic acid into the bladder wall is safe and if it works to reduce pain and urinary frequency in people with interstitial cystitis (IC), also called bladder pain syndrome (BPS).\n\nWho can take part? Adults aged 18 and older who have IC\u002FBPS that did not get better after at least two standard treatments (such as diet changes, oral drugs, or bladder instillations) for 6 months or more.\n\nMain questions the study aims to answer:\n\nWhat side effects (medical problems) do participants have after the injection procedure?\n\nDoes the injection lower pain and reduce how often a person needs to urinate, compared to before the treatment?\n\nWhat will happen in the study? There is no comparison group or placebo (a look-alike substance with no drug). All participants receive the same treatment.\n\nParticipants will:\n\nHave a one-time procedure under intravenous anesthesia (medicine that puts them to sleep)\n\nReceive 20 small injections of hyaluronic acid into the bladder wall using a thin tube with a camera (cystoscope)\n\nHave small tissue samples taken from the bladder (biopsy) during the same procedure\n\nKeep a 3-day diary of their urination\n\nFill out short questionnaires about pain, symptoms, and quality of life\n\nReturn for follow-up visits at 1 day, 1 week, 4 weeks, 3 and 6 months after the injection.\n\nAt the 4-week visit, participants will have cystoscopy with bladder biopsy and may receive a second injection if the first one helped.\n\nPossible benefits We cannot guarantee that this experimental treatment will help everyone. However, based on years of experience with similar hyaluronic acid injections in other body parts, researchers hope that injecting the substance directly into the bladder wall will give longer-lasting relief than standard bladder instillations.\n\nRisks and side effects\n\nThe most common expected side effects are:\n\nBlood in the urine for a few hours or days (usually goes away on its own) Temporary increase in pain or burning when urinating Infection (unlikely; the team will give antibiotics to lower the risk) Serious problems such as bladder wall puncture or allergic reaction are very rare.\n\nParticipation is voluntary People can join or leave the study at any time without giving a reason. Refusing or stopping will not affect their regular medical care at the hospital.\n\nConfidentiality All personal information will be kept private. Results will only be shared in combined, anonymous form (no names or identifying details).",[350,27],"Cystitis, Interstitial",[352,353,354],"Bladder Pain Syndrome","IC\u002FBPS","Hyaluronic Acid Injection","2026-06-20",{"date":203,"type":36},{"date":358,"type":23},"2026-07",{"date":360,"type":23},"2027-01",{"name":362,"class":363},"Sverdlovsk Regional Clinical Hospital No.1","NETWORK",{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":54,"phases":374,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":142},"100525590","phase-2-perioperative-vitamin-c-to-reduce-persistent-pain-after-total-knee-arthroplasty-100525590","NCT06123715","Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty","PeRiOperative VItamin C to Reduce perSistent paIn After tOtal kNee Arthroplasty (PROVISION): a Pilot Multicentre Randomized Controlled Trial","PROVISION","Inclusion Criteria:\n\n* Patients \\>18 years old\n* Undergoing a unilateral or bilateral primary total knee arthroplasty for advanced osteoarthritis of the knee\n\nExclusion Criteria:\n\n* TKA for infection (septic joint), fracture, ankylosing spondylitis, lupus, or psoriatic arthritis\n* History of kidney stones, acute or chronic renal failure, hemochromatosis, or glucose-6-phosphate deficiency\n* Unlikely to comply with follow-up (e.g., no fixed address, plans to move out of town)\n* Language difficulties that would impede valid completion of questionnaires\n* Planned staged bilateral TKA\n* Treating surgeon deems patient inappropriate for inclusion in trial\n* Any allergy or sensitivity to milk\n* Pregnant or planning to become pregnant during the study",{"count":373,"type":23},400,[375],"PHASE2","Phase II Multicentre, pilot, parallel-group, blinded, 1:1 randomized controlled trial to determine the feasibility of conducting a larger definitive trail of using vitamin C to reduce persistent pain in patients undergoing total knee arthroplasty surgery.",[27,378,156],"Knee Pain Chronic","2026-06-19",{"date":283,"type":36},{"date":382,"type":36},"2024-04-16",{"date":334,"type":23},{"name":385,"class":43},"University Health Network, Toronto",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":54,"phases":395,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":44},"100515263","emotional-awareness-and-expression-therapy-for-people-with-persistent-pain-following-orthopedic-trauma-100515263","NCT05989230","Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma","Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma: A Pilot Feasibility Study","Inclusion Criteria:\n\n* One or more acute orthopedic injuries\n* The patient sustained an orthopedic injury including, but not limited to:\n\n  * Pelvic or acetabulum fracture\n  * Open\u002Fdisplaced comminuted fracture of long bones\n  * Upper extremity injuries with a major nerve involvement\n  * Injuries with significant injuries to major blood vessels\n  * Traumatic amputation of big toe, thumb, or proximal to the wrist or ankle.\n* Initial admission to the trauma or orthopedic center\u002Fservice of the participating hospital OR all necessary screening and patient characteristic data available in medical record (determination based on information available at time of enrollment)\n* 18 years old or older\n* Received operative fixation for at least one acute orthopaedic injury at a participating hospital. Patients should be recruited at the time of primary injury, not revision or complication surgery\n* Average Brief Pain Inventory Score \\> 3\u002F10\n* Presence of pain most days (\\> 3 days\u002Fweek) for past three months\n\nExclusion Criteria:\n\n* peri-prosthetic fractures of the femur (regardless of etiology)\n* non-ambulatory due to an associated spinal cord injury\n* non-ambulatory pre-injury\n* currently pregnant\n* moderate or severe traumatic brain injury (TBI), as evidenced by intracranial hemorrhage present on admission CT\n* major amputation(s) of the upper or lower extremities\n* non-English speaking\n* Likely to have severe problems with maintaining follow-up for any of the following reasons:\n\n  * The patient has been diagnosed with a severe psychiatric conditions\n  * The patient has current alcohol and\u002For drug addiction based on medical record or patient self-report.\n  * The patient is intellectually challenged without adequate family support\n  * The patient lives outside the hospital's catchment area\n  * The patient follow-up is planned at another medical center\n  * The patient is a prisoner\n  * The patient is homeless\n  * Other",{"count":394,"type":23},30,[56],"The purpose of this single-arm trial is to determine the feasibility of emotional awareness and expression therapy (EAET) for individuals with persistent pain following orthopedic trauma. As part of this study, participants will be asked to attend weekly EAET treatment sessions and complete assessments (including pre-treatment, post-treatment, and follow-up) consisting of questionnaires and sensory testing procedures.",[398,27,399],"Orthopaedic Trauma","Musculoskeletal Injury","2026-06-17",{"date":402,"type":36},"2026-06-18",{"date":404,"type":36},"2024-08-28",{"date":406,"type":23},"2027-09-01",{"name":408,"class":43},"Johns Hopkins University",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":417,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":54,"phases":421,"briefSummary":422,"conditions":423,"keywords":426,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":44},"100492269","dance-therapy-and-chronic-pain-100492269","NCT05689944","Dance-therapy and Chronic Pain","Effect of Dance-therapy on Chronic Adolescent Pain Patients - a Randomized Controlled Trial Study","ALGODANCE","Inclusion Criteria:\n\n* Patients aged 12 to 20 years, girls or boys, with chronic pain.\n* Diagnosis of chronic pain made in a Pain Management Center\n* Patients followed in a Pain Management Center (to ensure that patients entering the protocol have pain that is not relieved by conventional treatments)\n* Patients who have given written consent for adults or whose parents have given consent for minors\n* Patients who are affiliated with or benefit from a social security system.\n\nExclusion Criteria:\n\n* Patients with other neurological or psychological disorders\n* Patients with psychiatric illnesses\n* Patients with chronic infectious, metabolic, cancerous, autoimmune diseases.\n* Non-communicating patients including deaf and hard of hearing patients\n* Patients or parents who do not speak or read French\n* Pregnant women\n* Dance or yoga professionals (dance or yoga teachers or those studying to become teachers)","12 Years","20 Years",{"count":420,"type":23},160,[56],"Pain, when it becomes chronic, can be a threat to patients and it is very common to observe a fear of pain and a fear of movement (kinesiophobia). Avoidance of movement due to fear of pain can lead to a deterioration of body image. Non-medicinal therapies are essential to correct this fear and movement avoidance behavior, to decrease \"catastrophic\" judgments and thus anxiety. The use of art-therapy in the accompaniment of patients with pain has shown, in particular, decreases in the intensity of pain, the level of anxiety, an improvement in stress, mood and overall psychological state. However, according to the current literature, it appears that 1) this technique is rarely used in children or adolescents, for whom non-medicinal therapies are fundamental, and 2) in the case of chronic pain, the form of art used is very rarely related to the body (most often painting, drawing, music...).\n\nIn this project, investigators propose to set up and test the potential benefit of art-therapy sessions related to the body, namely dance-therapy, in adolescents and young adults suffering from chronic pain.",[27,424,425],"Complex Regional Pain Syndromes","Tension-Type Headache",[427,428,429,430,431],"Dance-therapy","Chronic pain","Complex Regional Pain Syndrome","Tension Type Headache","Adolescents","2026-06-16",{"date":402,"type":36},{"date":435,"type":36},"2024-03-01",{"date":437,"type":23},"2030-10",{"name":439,"class":43},"Hospices Civils de Lyon",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":54,"phases":450,"briefSummary":451,"conditions":452,"keywords":456,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":44},"100631270","weighted-blanket-use-for-adults-with-chronic-pain-100631270","NCT07498491","Weighted Blanket Use for Adults With Chronic Pain","A Single-Arm Pilot Study Investigating Weighted Blanket Use for Chronic Pain","EMBRACE","Inclusion Criteria:\n\n* Age: Male and non-pregnant female adult participants must 18 years of age or older\n* Duration of pain: at least 3 months\n* Average Pain Intensity over the past week: ≥3\u002F10 NRS\n* Safely able to lift a weighted blanket that is 10% of the participant's self-reported body weight (10-25 lbs.) without assistance.\n* Willing to sleep with a weighted blanket (10-25 lbs.) for a total of 35 (7 days for Run-In\u002FAdjustment + 28 days of trial).\n* Willing to maintain current dietary patterns, activity level, and stable body weight for the duration of the study.\n* Willing to undergo study procedures, including completion of online questionnaires and surveys, and attend virtual study visits.\n* Informed Consent: Participants must be able to provide informed consent and comply with the study procedure.\n* Able to speak, read, and understand English.\n* Able to access WIFI to attend virtual visits and complete study surveys.\n\nExclusion Criteria:\n\n* Age: Participants younger than 18 years old.\n* Currently using a weighted blanket (will have opportunity for washout period)\n* Inability to lift a 10-25 lbs. (10% of body weight) weighted blanket without assistance.\n* Inability or unwillingness to sleep with the weighted blanket nightly\n* Breathing\u002FRespiratory Issue: Obstructive sleep apnea (OSA), Chronic obstructive Pulmonary Disease (COPD- includes emphysema and chronic bronchitis), Tuberculosis (TB), severe asthma\n* Cancer: Lung cancer\n* Cardiovascular Disease: Congestive heart failure (CHF), severe cardiomyopathy\n* Circulatory Issues: Severe peripheral artery disease (PAD), severe or uncontrolled Type 2 Diabetes\n* Recent surgery: Participants who recently had surgery and\u002For have an open wound.\n* Pregnancy or Lactation: Individuals who are pregnant, lactating, or planning a pregnancy within the next 35 days.\n* Co-sleeping: Individuals who co-sleep with their infant or young child.\n* Allergies: Known allergy or hypersensitivity to any component of the study products (including cotton material, natural and plant-based dyes).\n* Claustrophobia\n* Participation in Other Pain Trials: Currently participating in another pain research study.\n* Any condition that, in the opinion of the Investigator, does not justify the individuals' participation in the study that may impact their safety or confound trial results. This includes an increase in the participants' pain intensity during the baseline week or the active part of the trial.",{"count":449,"type":23},44,[56],"Chronic pain is a common condition that can affect sleep, daily functioning, and overall quality of life. Many individuals living with chronic pain seek non-medication approaches to help manage their symptoms. Weighted blankets are commonly used to promote relaxation and comfort during sleep, but there is limited research examining their potential role in supporting people with chronic pain.\n\nThis pilot study will explore the experiences of adults with chronic pain who use a weighted blanket during sleep. The study aims to better understand whether nightly use of a weighted blanket may be associated with changes in pain, sleep, and daily functioning. Findings from this study will help inform future research on non-medication approaches to managing chronic pain.\n\nApproximately 44 adults with chronic pain will participate in the study. Participation will last about five weeks. After completing a virtual enrollment visit and baseline questionnaires, participants will receive a weighted blanket sized to approximately 10 percent of their body weight.\n\nParticipants will first complete a 7-day adjustment period using the blanket while sleeping. If they tolerate the blanket and use it nightly during this period, they will continue into a 4-week study phase in which they will use the weighted blanket each night.\n\nDuring the study, participants will complete brief online surveys about their experiences and adherence to using the blanket. Pain and quality-of-life questionnaires will be completed at multiple time points, including at the start and end of the study. Participants will also provide feedback about their experience using the weighted blanket.\n\nResults from this pilot study will help researchers better understand how weighted blankets may be used by adults with chronic pain and may help guide the design of future studies evaluating non-pharmacologic approaches to pain management.",[27,453,454,455],"Musculoskeletal Pain","Sleep Disturbance","Pain Disorders",[280,457,458,459,460],"weighted blanket","pain management","non-pharmacologic pain management","sleep intervention","2026-06-15",{"date":400,"type":36},{"date":464,"type":36},"2026-05-27",{"date":466,"type":23},"2026-09-15",{"name":468,"class":43},"National University of Natural Medicine",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":173,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":44},"100614495","emotional-intelligence-and-chronic-orofacial-pain-100614495","NCT07280338","Emotional Intelligence and Chronic Orofacial Pain","IEDOF","Inclusion Criteria:\n\nFor all subjects:\n\nMajor subject\n\n* Non-opposition obtained\n* For subjects in the TMD group:\n\nDiagnosis of temporomandibular dysfunction -No other diagnosis of chronic pain\n\nFor subjects in the control group:\n\n-No diagnosis of chronic pain\n\nNon inclusion Criteria:\n\n* Subject not understanding French\n* Subject under legal protection (guardianship or curatorship)\n* Refusal to participate",{"count":477,"type":23},88,"Chronic pain, lasting more than three months, is a widespread health issue that negatively impacts daily life, leading to significant emotional distress and functional impairment. Emotional intelligence, defined as the ability to recognize and manage one's own emotions as well as those of others, has been linked to better communication skills and reduced stress, which is a well-known risk factor for chronic pain. Studies have highlighted a correlation between emotional intelligence and certain chronic pain conditions, such as fibromyalgia and migraines. However, no research has yet explored its role in painful temporomandibular disorders (TMD). Given the strong involvement of psychosocial factors in TMD etiology, a better understanding of these elements could improve pain management and pave the way for preventive interventions.",[27],[481],"Emotional intelligence",{"date":432,"type":36},{"date":484,"type":36},"2026-02-09",{"date":486,"type":23},"2027-02-09",{"name":488,"class":43},"University Hospital, Brest",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":496,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":54,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":44},"100605292","culturally-adapted-mobile-treatment-of-chronic-pain-in-adolescent-survivors-of-pediatric-cancer-a-randomized-clinical-trial-100605292","NCT07160621","Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer: A Randomized Clinical Trial","ADAPTED2","Inclusion Criteria:\n\n* Adolescent Participants\n\n  * 10-17-year-old survivors of childhood cancer or those who received cancer directed therapies (e.g., Langerhan's Histiocytosis)\n  * At least one-year post treatment completion\n  * Pain present for 3 months or longer\n  * Pain interfering with at least one area of daily functioning\n* Parent\u002FCaregiver Participants\n\n  * ≥ 18 years of age\n  * Legally authorized to provide informed consent for the adolescent participant\n\nExclusion Criteria:\n\n* Adolescent Participants\n\n  * Serious comorbid psychiatric condition\n  * Current substance abuse as determined by the Substance Use Screening Questionnaire\n  * History of development delay or significant cognitive impairment\n\n    * Note: A participant who completed the feasibility study (ADAPTED) cannot participate in the subsequent clinical trial (ADAPTED2)\n* Parent\u002FCaregiver Participants\n\n  * Not fluent in English or Spanish\n  * Unable to provide consent for own participation or for the participation of the adolescent participant","10 Years","17 Years",{"count":499,"type":23},228,[56],"The purpose of the study is to determine if an adapted mobile cognitive behavioral therapy (CBT) app (WebMAP Onc) is more effective than standard pain education in reducing chronic pain and improving daily functioning in adolescent survivors of pediatric cancer.\n\nThis randomized study led by St. Jude Children's Research Hospital will involve 228 participants (114 adolescent survivors and 114 caregivers) across four U.S. hospitals. Outcomes include pain reduction, improved function, and the role of social determinants of health. Assessments occur at baseline, post-treatment, and 3-month follow-up.",[503,27],"Childhood Cancer Survivor",[505,506],"Adult Caregiver","Adolescent Survivor",{"date":400,"type":36},{"date":509,"type":36},"2025-09-05",{"date":511,"type":23},"2029-01",{"name":513,"class":43},"St. Jude Children's Research Hospital",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":521,"targetDuration":4,"studyType":54,"phases":523,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":44},"100533438","placebo-impacts-sleep-and-pain-modulation-in-chronic-pain-100533438","NCT06225817","Placebo Impacts Sleep and Pain Modulation in Chronic Pain","The Impact of Open-label Placebo on Sleep and Pain Modulation","Inclusion Criteria:\n\n* Age ( 18-88 years old)\n* English speaker (written and spoken)\n* TMD for at least 3 months\n* Grade Chronic Pain Scale (GCPS) ≥1\n* Smartphone\u002Ftext messaging capability\n\nExclusion Criteria:\n\n* Present or past degenerative neuromuscular disease\n* Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years\n* Any personal (or family first degree) history of mania, schizophrenia, or other psychoses\n* Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.\n* Lifetime alcohol\u002Fdrug dependence or alcohol\u002Fdrug abuse in past 3 months\n* Pregnancy or breast feeding\n* Impaired or uncorrected hearing",{"count":522,"type":23},111,[56],"The goal of this free-choice parallel design clinical trial is to examine the potential beneficial effects of using open-label placebo (OLP) in improving chronic pain related outcomes and sleep quality in people with temporomandibular disorders. This study will enroll a cohort of participants with temporomandibular disorders (TMD) which lasts for more than 3 months. The main questions it aims to answer are:\n\n1. Will participants with TMD be more likely to take open-label placebo pills if they are introduced to the effects of placebo (e.g., going through an expectation management session)?\n2. Will taking open-label placebo plus expectation management improve chronic pain related outcomes, such as chronic pain intensity, interference, levels of anxiety and depression, in the cohort of TMD?\n3. Will open-label placebo plus expectation management improve sleep quality in participants suffering from TMD?\n\nTo answer the above questions, participants with TMD will be randomly assigned to three groups: 1. Open-label placebo plus expectation management group, where participants will complete a 1-hour discussion session about their expectations toward open-lable placebo intervention, and then take 1 open-labe placebo pill per day for a total of 45 days. 2. Open-label placebo only group where participants will be asked to take open-label placebo pills, one pill per day, for a total of 45 days. 3. standard of care group where participants will maintain their usual care without introducing open-label placebo to them during the 45 days monitoring. Researchers will compare the chronic pain intensity, interference, mood, anxiety, and sleep quality between the open-label placebo group and the wait-list group. Daily chronic pain will be measured using visual analog scale (VAS) ranging from 0=no pain at all to 100=maximum tolerable pain. Chronic pain interference using Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference and pain behavior. Anxiety and depression will be measured using PROMIS-anxiety, and PROMIS-depression scales respectively. Finally, sleep quality will be quantified using the objective measurement Motion Watch during the 45 days intervention and monitoring. In order to have a rigorous measurement of the baseline pain and sleep fluctuation, this study will include a 7-day phenotyping period before the starting of the 45-day intervention and monitoring. During the 7-day phenotyping period, participants will record their daily chronic pain and sleep quality using polysomnography.",[27,526],"Headache",{"date":400,"type":36},{"date":529,"type":36},"2025-04-21",{"date":531,"type":23},"2028-07-30",{"name":210,"class":43},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":18,"minAge":274,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":54,"phases":543,"briefSummary":544,"conditions":545,"keywords":547,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":4},"100642654","virtual-reality-for-pain-and-well-being-in-older-adults-100642654","NCT07607899","Virtual Reality for Pain and Well-Being in Older Adults","Moving Without Fear or Pain: Use of Immersive Virtual Reality to Reduce Pain and Improve Well-Being in Older Adults","VitaMove","Inclusion Criteria:\n\n* Age 65 years or older\n* Able to understand and communicate in French\n* Chronic pain lasting 6 months or longer\n* Average pain intensity of 3 or greater on a 0-10 Numeric Rating Scale during the week prior to enrollment\n* Score greater than 25 on the 11-item Tampa Scale of Kinesiophobia (TSK-11)\n* No neurocognitive impairment (Mini-Mental State Examination \\[MMSE\\] ≥ 24), or mild neurocognitive impairment (MMSE 18-24) with preserved capacity to consent (University of California Brief Assessment of Capacity to Consent \\[UBACC\\] score ≥ 12)\n* Normal or corrected-to-normal visual acuity\n\nExclusion Criteria:\n\n* Severe motion sickness or intolerance that would prevent safe use of a virtual reality headset (experimental group only)\n* Medical condition that would prevent safe participation in rehabilitation activities\n* Presence of open wounds or infection at painful or contralateral sites",{"count":542,"type":23},24,[56],"Chronic pain is common among adults aged 65 and older and can reduce mobility, independence, mood, and quality of life. Many older adults also develop a fear of movement because they worry that physical activity will increase their pain or cause injury. This fear can lead to reduced activity, physical deconditioning, and further loss of independence. This study aims to evaluate the feasibility, acceptability, and potential impact of Moving Without Fear or Pain, a program combining structured pain education (Empowered Relief) with immersive virtual reality rehabilitation to gradually reintroduce movement in a safe and engaging way. Empowered Relief is a single-session, two-hour online pain education class delivered by a trained health professional. It explains how chronic pain affects the brain and nervous system and teaches strategies to calm the nervous system, manage pain flare-ups, reduce pain-related worry and catastrophizing, and increase confidence in movement and daily activities.\n\nThe virtual reality intervention includes up to eight individualized sessions over approximately one month. Sessions last 5 to 30 minutes and are supervised by a trained clinician. Participants wear a virtual reality headset and are immersed in calming or engaging environments, such as nature settings. Depending on their comfort and abilities, sessions may begin with passive guided motor imagery and progress to active movement within interactive virtual environments. Some applications allow participants to control movement in the virtual world through gentle physical activity, such as stepping or upper-body movement. The intervention is personalized to each participant's physical capacity, preferences, and rehabilitation goals. The aim is to reduce fear of movement, increase confidence, and promote safe re-engagement in physical activity. In this pilot randomized controlled trial, 24 older adults with chronic pain will be randomly assigned to one of two groups: 1) Experimental Group: Participants will receive the Empowered Relief pain education course, usual care, and up to eight immersive virtual reality rehabilitation sessions. 2) Control Group: Participants will receive the Empowered Relief pain education course and usual care, without virtual reality sessions. The findings will inform a larger future study.",[27,546],"Kinesiophobia (Fear of Movement)",[27,548,549,550,551,552,553,554,555],"Older Adults","Kinesiophobia","Fear of Movement","Empowered Relief","Biopsychosocial Model","Motor Imagery","Virtual Reality Rehabilitation","Non-Pharmacological Pain Management","2026-06-12",{"date":432,"type":36},{"date":559,"type":23},"2026-06",{"date":561,"type":23},"2027-03",{"name":563,"class":43},"Laval University",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":572,"targetDuration":574,"studyType":24,"phases":4,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":44},"100642150","outcomes-registry-after-ketamine-infusions-for-chronic-pain-a-longitudinal-evaluation-100642150","NCT07648771","Outcomes Registry After Ketamine Infusions for Chronic Pain: A Longitudinal Evaluation","Nationwide Observational Registry of Patient Outcomes Following Ketamine Infusion Therapy for Chronic Pain","ORACLE","Inclusion Criteria:\n\n* Planning to receive an intravenous ketamine infusion for the treatment of chronic pain\n\nExclusion Criteria:\n\n* Unable to read or understand English questionnaires",{"count":573,"type":23},800,"16 Weeks","Ketamine is an anesthetic drug that is sometimes used to relieve chronic pain. The goal of this observational study is to learn about how patients respond to ketamine infusions for chronic pain.\n\nNote: This study does not provide ketamine - instead, this study uses surveys to follow patients who are already scheduled to receive ketamine infusions as part of their regular medical care.\n\nWe will also follow a second group of patients who were recommended ketamine infusions by their doctor but were denied insurance coverage for this treatment. These participants will complete the same surveys for up to 16 weeks, starting from when their treatment was originally scheduled. Comparing this group to patients who received ketamine will help researchers better understand ketamine's effects and how insurance denials affect chronic pain patients.",[27,577],"Ketamine",[579,580,581,582,577,27,583],"Observational","Registry","Longitudinal","Surveys","Analgesia",{"date":461,"type":36},{"date":586,"type":23},"2026-08",{"date":588,"type":23},"2034-12",{"name":590,"class":43},"Stanford University",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":54,"phases":600,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":291},"100641167","clinical-evaluation-of-the-epifaith-syringe-in-epidural-pain-management-100641167","NCT07654907","Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management","Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management: A Prospective, Open-Label, Non-Randomized Comparative Study Versus Conventional Loss-of-Resistance Technique","Inclusion Criteria:\n\n* Age 18 years or older at the time of informed consent.\n* Scheduled to undergo a clinically indicated interventional pain management procedure as part of routine clinical care at the study site.\n* Planned procedure requires epidural space localization using the loss-of-resistance technique and is compatible with use of either a conventional loss-of-resistance syringe or the EpiFaith™ syringe, in the judgment of the treating clinician.\n* Eligible procedure types include cervical, thoracic, lumbar, or caudal epidural procedures; minimally invasive lumbar decompression (MILD) procedures when epidural access or localization is required; and spinal cord stimulation (SCS) trial epidural access procedures.\n* Able and willing to provide written informed consent before any study-specific data collection.\n* Able and willing to comply with post-procedure follow-up assessments through approximately 1 week after the procedure, including telephone or telehealth follow-up when applicable.\n* For participants receiving anticoagulant or antiplatelet therapy, the treating clinician must determine that the participant can safely undergo the planned epidural procedure according to standard institutional practice and applicable neuraxial anticoagulation guidance.\n\nExclusion Criteria:\n\n* Inability to provide written informed consent independently, including adults who require consent by a legally authorized representative.\n* Known contraindication to the planned epidural procedure, including active infection at the puncture site, uncontrolled coagulopathy, or anticoagulant or antiplatelet status that precludes the planned procedure in the judgment of the treating clinician.\n* Known hypersensitivity or contraindication to any standard-of-care medication, contrast agent, or procedural material required for the planned epidural procedure, where such contraindication precludes the procedure.\n* Participation in another interventional clinical trial that, in the investigator's judgment, would confound interpretation of study endpoints.\n* Any medical, anatomic, procedural, or clinical condition that, in the investigator's judgment, would make study participation unsafe or not in the participant's best interest.\n* Pregnancy, unless the epidural procedure is clinically indicated and permitted under the enrolling site's standard clinical practice and IRB-approved procedures.\n* Unwillingness or inability to complete required study assessments through approximately 1 week after the procedure.",{"count":599,"type":23},100,[56],"This study evaluates a new medical device called the EpiFaith™ Syringe, which is designed to help clinicians more accurately identify the epidural space during pain management procedures. The epidural space is a narrow area near the spine where medication is delivered to treat chronic pain conditions. Finding this space correctly is a critical step in procedures such as epidural steroid injections, spinal cord stimulator placement, and minimally invasive lumbar decompression (MILD).\n\nCurrently, clinicians locate the epidural space using a method called loss-of-resistance (LOR), which relies on the feel of a syringe plunger as a needle is advanced toward the epidural space. This technique depends on the clinician's experience and touch, and can sometimes result in multiple needle attempts or an incorrect signal that the epidural space has been reached when it has not.\n\nThe EpiFaith™ Syringe is designed to provide a clear visual signal, called the Faith Signal, at the moment the epidural space is entered, reducing reliance on touch alone. The device is used with standard epidural needles and does not require additional equipment or significant changes to routine procedure workflow.\n\nThis study will enroll 100 adults scheduled for a clinically indicated epidural pain procedure at Innovative Pain Treatment Solutions in Temecula or San Diego, California. Participants will be assigned to have their procedure performed using either the EpiFaith™ Syringe or a standard LOR syringe. The study will compare the number of needle attempts needed to access the epidural space and the rate of false signals between the two methods. Safety and patient-reported pain outcomes will also be collected for approximately one week following the procedure.",[27],{"date":400,"type":36},{"date":605,"type":23},"2026-05-28",{"date":607,"type":23},"2026-12-28",{"name":609,"class":43},"Flat Medical Co., Ltd",{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":18,"minAge":417,"maxAge":497,"enrollmentInfo":618,"targetDuration":4,"studyType":54,"phases":620,"briefSummary":622,"conditions":623,"keywords":624,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":634},"100515935","phase-3-analgesic-effectiveness-of-capsaicin-8-cutaneous-patch-in-children-100515935","NCT05997979","Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children","Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch for the Treatment of Chronic Postsurgical or Post-traumatic Neuropathic Pain: a Randomized Placebo Controlled Study in Children Aged 12 to 17-y","CAPSAPED","Inclusion Criteria:\n\n* Children aged 12 to 17 years (lower age limit of 12 has been chosen to ensure NPSI full filling).\n* Male or female.\n* Persistent neuropathic pain more than 3 months after surgery or trauma despite treatment following recommendations.\n* Neuropathic pain is defined as a DN4 score equal to or greater than 3\u002F7 or 4\u002F10, and localized in a nerve territory explained by the surgery or the trauma.\n* Treatment, survey and follow up must be realized in an identified investigating center of the study\n* For patients of childbearing potential: use of an adequate method of contraception\\* during the course of the study through 48 hours after the last patch application (girls of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the first patch application).\n\n  * Adequate contraception includes sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide, combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)\n\nExclusion Criteria:\n\n* Intellectual deficiency not allowing full filling of NPSI.\n* Insufficient command of the French language to full fill NPSI and other evaluation tools.\n* Parents' refusal of consent.\n* Minor patients' opposition.\n* Underlying neurological disease.\n* Ongoing neurotoxic treatment.\n* Already treated by capsaicin.\n* Cutaneous lesion on pain area.\n* Patient presenting a pain area on the face, above the hairline of the scalp, and\u002For in proximity to mucous membranes\n* Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of Qutenza SmPC.",{"count":619,"type":23},46,[621],"PHASE3","This study concerns children aged to 12 to 17-years with local chronic neuropathic pain after trauma or surgery.\n\nIt is a multicentric randomized controlled superiority trial in parallel arms :\n\n* experimental arm: Capsaicin 8% cutaneous patch\n* controlled arm : Hydrocolloid dressing\n\nTreatment with capsaicin application is realized at baseline, and repeated 3 months after the first patch application if needed.\n\nTolerance is assessed during each application and by phone call in following days until stop of cold need.\n\nEfficacy is assessed monthly by clinical consultation until the end of the study (month 4).",[325,27],[325,625,626,627],"Pediatric","Capsaicin","Randomized clinical trial",{"date":461,"type":36},{"date":630,"type":36},"2024-03-05",{"date":632,"type":23},"2028-07-05",{"name":488,"class":43},10]